Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL

Giovanni Palladini, Francesca Lavatelli, Paola Russo, Stefano Perlini, Vittorio Perfetti, Tiziana Bosoni, Laura Obici, Arthur R. Bradwell, GianVico Melzi D'Eril, Roberto Fogari, Remigio Moratti, Giampaolo Merlini

Research output: Contribution to journalArticle

Abstract

N-terminal natriuretic peptide type B (NT-proBNP) is a marker of cardiac dysfunction in light chain amyloidosis (AL) and a powerful prognostic determinant. Serum NT-proBNP and circulating free light chains (FLCs) were measured at enrollment and after 3 cycles of chemotherapy in 51 patients with cardiac AL. In patients (n = 22, 43%) in whom FLCs decreased by more than 50% (hematologic response), NT-proBNP concentration decreased by a median of 48%, whereas in the remaining patients it increased by 47% (P = .01). The reduction of NT-proBNP was greater in patients (n = 9) in whom amyloidogenic FLCs disappeared at immunofixation (median 53%), than in the remaining responding patients (median 31%, P = .04). Left ventricular wall thickness decreased by at least 2 mm in 3 of 20 patients in whom NT-proBNP improved. Fifteen patients died. Thirteen of them, in whom NT-proBNP and FLCs did not improve, died after a median of 1.8 months. The decrease of FLCs translates into a simultaneous decrease of NT-proBNP and improved survival. Patients in whom chemotherapy fails to induce such a decrease are at risk of early death. Cardiac function in AL can rapidly improve due to a reduction of the circulating amyloidogenic precursor, despite the amount of cardiac amyloid deposits remaining apparently unaltered, as measured by echocardiography.

Original languageEnglish
Pages (from-to)3854-3858
Number of pages5
JournalBlood
Volume107
Issue number10
DOIs
Publication statusPublished - May 15 2006

Fingerprint

Brain Natriuretic Peptide
Amyloidosis
Association reactions
Light
Survival
Serum
Chemotherapy
Echocardiography
Drug Therapy
pro-brain natriuretic peptide (1-76)
Amyloid
Amyloid Plaques
Deposits

ASJC Scopus subject areas

  • Hematology

Cite this

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. / Palladini, Giovanni; Lavatelli, Francesca; Russo, Paola; Perlini, Stefano; Perfetti, Vittorio; Bosoni, Tiziana; Obici, Laura; Bradwell, Arthur R.; D'Eril, GianVico Melzi; Fogari, Roberto; Moratti, Remigio; Merlini, Giampaolo.

In: Blood, Vol. 107, No. 10, 15.05.2006, p. 3854-3858.

Research output: Contribution to journalArticle

@article{2b4097b770b042b38e0dab9bd30f6f54,
title = "Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL",
abstract = "N-terminal natriuretic peptide type B (NT-proBNP) is a marker of cardiac dysfunction in light chain amyloidosis (AL) and a powerful prognostic determinant. Serum NT-proBNP and circulating free light chains (FLCs) were measured at enrollment and after 3 cycles of chemotherapy in 51 patients with cardiac AL. In patients (n = 22, 43{\%}) in whom FLCs decreased by more than 50{\%} (hematologic response), NT-proBNP concentration decreased by a median of 48{\%}, whereas in the remaining patients it increased by 47{\%} (P = .01). The reduction of NT-proBNP was greater in patients (n = 9) in whom amyloidogenic FLCs disappeared at immunofixation (median 53{\%}), than in the remaining responding patients (median 31{\%}, P = .04). Left ventricular wall thickness decreased by at least 2 mm in 3 of 20 patients in whom NT-proBNP improved. Fifteen patients died. Thirteen of them, in whom NT-proBNP and FLCs did not improve, died after a median of 1.8 months. The decrease of FLCs translates into a simultaneous decrease of NT-proBNP and improved survival. Patients in whom chemotherapy fails to induce such a decrease are at risk of early death. Cardiac function in AL can rapidly improve due to a reduction of the circulating amyloidogenic precursor, despite the amount of cardiac amyloid deposits remaining apparently unaltered, as measured by echocardiography.",
author = "Giovanni Palladini and Francesca Lavatelli and Paola Russo and Stefano Perlini and Vittorio Perfetti and Tiziana Bosoni and Laura Obici and Bradwell, {Arthur R.} and D'Eril, {GianVico Melzi} and Roberto Fogari and Remigio Moratti and Giampaolo Merlini",
year = "2006",
month = "5",
day = "15",
doi = "10.1182/blood-2005-11-4385",
language = "English",
volume = "107",
pages = "3854--3858",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL

AU - Palladini, Giovanni

AU - Lavatelli, Francesca

AU - Russo, Paola

AU - Perlini, Stefano

AU - Perfetti, Vittorio

AU - Bosoni, Tiziana

AU - Obici, Laura

AU - Bradwell, Arthur R.

AU - D'Eril, GianVico Melzi

AU - Fogari, Roberto

AU - Moratti, Remigio

AU - Merlini, Giampaolo

PY - 2006/5/15

Y1 - 2006/5/15

N2 - N-terminal natriuretic peptide type B (NT-proBNP) is a marker of cardiac dysfunction in light chain amyloidosis (AL) and a powerful prognostic determinant. Serum NT-proBNP and circulating free light chains (FLCs) were measured at enrollment and after 3 cycles of chemotherapy in 51 patients with cardiac AL. In patients (n = 22, 43%) in whom FLCs decreased by more than 50% (hematologic response), NT-proBNP concentration decreased by a median of 48%, whereas in the remaining patients it increased by 47% (P = .01). The reduction of NT-proBNP was greater in patients (n = 9) in whom amyloidogenic FLCs disappeared at immunofixation (median 53%), than in the remaining responding patients (median 31%, P = .04). Left ventricular wall thickness decreased by at least 2 mm in 3 of 20 patients in whom NT-proBNP improved. Fifteen patients died. Thirteen of them, in whom NT-proBNP and FLCs did not improve, died after a median of 1.8 months. The decrease of FLCs translates into a simultaneous decrease of NT-proBNP and improved survival. Patients in whom chemotherapy fails to induce such a decrease are at risk of early death. Cardiac function in AL can rapidly improve due to a reduction of the circulating amyloidogenic precursor, despite the amount of cardiac amyloid deposits remaining apparently unaltered, as measured by echocardiography.

AB - N-terminal natriuretic peptide type B (NT-proBNP) is a marker of cardiac dysfunction in light chain amyloidosis (AL) and a powerful prognostic determinant. Serum NT-proBNP and circulating free light chains (FLCs) were measured at enrollment and after 3 cycles of chemotherapy in 51 patients with cardiac AL. In patients (n = 22, 43%) in whom FLCs decreased by more than 50% (hematologic response), NT-proBNP concentration decreased by a median of 48%, whereas in the remaining patients it increased by 47% (P = .01). The reduction of NT-proBNP was greater in patients (n = 9) in whom amyloidogenic FLCs disappeared at immunofixation (median 53%), than in the remaining responding patients (median 31%, P = .04). Left ventricular wall thickness decreased by at least 2 mm in 3 of 20 patients in whom NT-proBNP improved. Fifteen patients died. Thirteen of them, in whom NT-proBNP and FLCs did not improve, died after a median of 1.8 months. The decrease of FLCs translates into a simultaneous decrease of NT-proBNP and improved survival. Patients in whom chemotherapy fails to induce such a decrease are at risk of early death. Cardiac function in AL can rapidly improve due to a reduction of the circulating amyloidogenic precursor, despite the amount of cardiac amyloid deposits remaining apparently unaltered, as measured by echocardiography.

UR - http://www.scopus.com/inward/record.url?scp=33646597285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646597285&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-11-4385

DO - 10.1182/blood-2005-11-4385

M3 - Article

C2 - 16434487

AN - SCOPUS:33646597285

VL - 107

SP - 3854

EP - 3858

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -